Form 4: Phibro CEO Bendheim Sells PAHC Shares

Phibro Animal Health Corp's President and CEO, Jack Bendheim, and BFI Co., LLC, executed pre-planned sales of Class A Common Stock totaling 30,337 shares.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corp, and BFI Co., LLC, reported transactions involving PAHC Class A Common Stock.
• On November 11, 2025, 15,000 shares of Class B Common Stock were converted into Class A Common Stock at a price of $0.
• Between November 12 and November 13, 2025, BFI Co., LLC sold a total of 30,337 Class A Common Stock shares.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 30, 2025.
• Weighted average sale prices ranged from $44.3689 to $45.2255 per share.
• Following these transactions, BFI Co., LLC indirectly holds 5,240 Class A Common Stock and 20,046,034 Class B Common Stock.
• Jack Bendheim directly holds 16,840 Class A Common Stock.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider sales by the CEO and a major shareholder, even though they were pre-planned. While 10b5-1 plans mitigate the immediate negative implication of timing, the reduction in insider holdings can still be perceived as a lack of conviction or a move to diversify away from the company's stock.

Negatives

• Insider sales by a key executive (President and CEO) and a significant owner (10% owner) could be perceived negatively by the market, potentially signaling a lack of confidence or a desire to diversify holdings.

Related Party Transactions

• BFI Co., LLC, which executed the sales, is directly controlled by Jack Bendheim, the President and CEO of Phibro Animal Health Corp, making these related-party transactions.

Stakeholder Impact

• Shareholders: May interpret the insider sales as a negative signal, potentially leading to downward pressure on the stock price.
• Management/Employees: No direct impact mentioned, but a significant insider sale could affect morale or perception of leadership's commitment.

Key Dates

Recommendation

The significant insider sales by the CEO and a major shareholder are a negative signal, as they reduce insider ownership. However, the sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the decision to sell was made in advance and not necessarily based on recent adverse developments. Investors should monitor future filings and company performance, but this event alone does not warrant a strong 'sell' recommendation without additional fundamental analysis. A 'hold' position is prudent given the mixed implications.

Keywords

Phibro Animal Health Corp, PAHC, Jack Bendheim, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, CEO, 10% Owner, Equity Transaction